- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 03.10. | Vor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 84 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September... ► Artikel lesen | |
| 29.09. | Vor Bio to present telitacicept data for Sjögren's disease at ACR meeting | 3 | Investing.com | ||
| 29.09. | Vor Biopharma: Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025 | 4 | GlobeNewswire (USA) | ||
| 25.09. | Vor Biopharma stock drops after filing to register warrant shares | 3 | Investing.com | ||
| 25.09. | Vor Biopharma-Aktie fällt nach Anmeldung von Aktien aus Optionsscheinen | 2 | Investing.com Deutsch | ||
| 24.09. | Vor Biopharma registers 51M shares for resale linked to RemeGen deal and PIPE financing | 1 | Seeking Alpha | ||
| 24.09. | Vor Biopharma Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 24.09. | Vor Biopharma upgraded to Buy at Stifel on telitacicept prospects | 2 | Seeking Alpha | ||
| 24.09. | Stifel upgrades Vor Biopharma stock to Buy on telitacicept prospects | 1 | Investing.com | ||
| 24.09. | Stifel stuft Vor Biopharma hoch - Potenzial von Telitacicept treibt Kursziel auf 55 US-Dollar | 1 | Investing.com Deutsch | ||
| 19.09. | Vor Biopharma trading halted on Thursday, news pending | 2 | Seeking Alpha | ||
| 17.09. | Vor Bio to present phase 3 data on telitacicept for myasthenia gravis | 2 | Investing.com | ||
| 17.09. | Vor Biopharma: Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM | 2 | GlobeNewswire (USA) | ||
| 17.09. | Vor Biopharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.09. | Vor Biopharma: Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum | 1 | GlobeNewswire (USA) | ||
| 27.08. | Vor Bio's Investigational Drug Scores Phase 3 Win In Autoimmune Kidney Disease Trial | 4 | Benzinga.com | ||
| 27.08. | Wechsel im Verwaltungsrat von Vor Biopharma: Drei Rücktritte und eine Neubesetzung | 4 | Investing.com Deutsch | ||
| 27.08. | Vor Bio, RemeGen late-stage trial of telitacicept in IgA nephropathy meets primary goal | 2 | Seeking Alpha | ||
| 27.08. | Vor Biopharma stock rises after collaborator's IgAN drug hits endpoint | 2 | Investing.com | ||
| 27.08. | Vor Biopharma: Aktionäre genehmigen Änderungen am Aktienplan und Aktienzusammenlegung | 3 | Investing.com Deutsch |
1 2 3 4 5 Weiter >>
82 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EDITAS MEDICINE | 3,185 | -0,44 % | Editas Medicine, Inc. - 8-K, Current Report | ||
| SOL GLOBAL INVESTMENTS | 0,030 | +2,73 % | SOL Global Investments Corp.: SOL Global CEO Davide Marcotti Charts Strategic Growth Path with International Investor Outreach | Toronto, Ontario--(Newsfile Corp. - September 22, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company") is pleased to provide an update under the... ► Artikel lesen | |
| TRINITY BIOTECH | 1,060 | -6,19 % | Trinity Biotech plc: Trinity Biotech Regains Compliance with Nasdaq Listing Requirements | DUBLIN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions... ► Artikel lesen | |
| FATE THERAPEUTICS | 1,444 | +2,52 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 18,905 | -3,94 % | Arcturus Therapeutics Holdings Inc. - 8-K, Current Report | ||
| OVID THERAPEUTICS | 1,430 | -0,69 % | Ovid Therapeutics Inc.: Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds | NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant... ► Artikel lesen | |
| EQUILLIUM | 1,234 | 0,00 % | Equillium, Inc.: Equillium Announces Leadership and Corporate Updates | LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 8,890 | -7,01 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants | EMERYVILLE, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 16,950 | -8,08 % | Regencell Bioscience Holdings Limited Announces Forward Stock Split | HONG KONG, June 2, 2025 - Regencell Bioscience Holdings Limited (Nasdaq: RGC) (the "Company"), today announced that its board of directors approved a 38-for-one forward stock split to be paid in the... ► Artikel lesen | |
| GENERATION BIO | 6,110 | -2,86 % | Generation Bio Co.: Generation Bio Announces 1-for-10 Reverse Stock Split | CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases... ► Artikel lesen | |
| CABALETTA BIO | 2,305 | -19,12 % | Cabaletta CAR-T wipes out B cells without preconditioning in small autoimmune trial | ||
| LONGEVERON | 0,810 | -8,43 % | Longeveron Announces Key Leadership Updates | Than Powell, Chief Business Officer and head of business development, appointed Interim CEODr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of DirectorsWa'el... ► Artikel lesen | |
| PROKIDNEY | 3,010 | -8,79 % | ProKidney: Hoffnung für Patienten, Chance für Investoren | Die Forschung im Bereich der Nierenerkrankungen entwickelt sich rasant, und neue Therapieansätze rücken in den Fokus von Investoren und Fachwelt. Besonders spannend ist die Frage, ob ProKidney mit seiner... ► Artikel lesen | |
| ATHIRA PHARMA | 3,940 | 0,00 % | Athira Pharma, Inc.: Athira Pharma Announces Reverse Stock Split | BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. ("Athira" or "Company") (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore... ► Artikel lesen | |
| BOLT PROJECTS | 3,600 | -5,26 % | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen |
Das Unternehmen VOR BIOPHARMA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 31,100 Euro und damit -1,95 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.